Article
Clinical Activity of Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumor Harboring Heterogeneous KIT/PDGFRA Mutations in the Phase III INVICTUS Study.
Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Dec 2021
Bauer Sebastian, Heinrich Michael C, George Suzanne, Zalcberg John R, Serrano César, Gelderblom Hans, Jones Robin L, Attia Steven, D'Amato Gina, Chi Ping, Reichardt Peter, Meade Julie, Su Ying, Ruiz-Soto Rodrigo, Blay Jean-Yves, von Mehren Margaret, Schöffski Patrick
Abstract excerpt
PURPOSE: Most patients with gastrointestinal stromal tumor (GIST) have activating mutations in KIT/PDGFRA and are initially responsive to tyrosine kinase inhibitors (TKI). The acquisition of secondary mutations leads to refractory/relapsed disease. This study reports the results of an analysis from the phase III INVICTUS study (NCT03353753) characterizing the genomic heterogeneity of tumors from patients with...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.